P16基因对膀胱癌细胞系BIU-87恶性生长抑制作用的研究

为了探讨P16基因在人膀胱癌中的肿瘤抑制作用及其在膀胱癌抑癌基因替代治疗中的潜在价值,构建了P16基因表达载体并将其导入有内源性P16基因缺失的人膀肤癌细胞系BIU-87中,观察转染细胞的生长速率、双层软琼脂集落试验及细胞周期的改变,发现转染了P16的细胞生长速率明显降低,软琼脂克隆形成能力显著下降,细胞周期出现向G1／G0期移行的特征性动力学改变。结果表明,P16基因对膀胱癌细胞的恶性增殖具有明显的抑制作用,是膀胱癌抑癌基因替代治疗的一个极有希望的候选靶基因,具有良好的应用前景。     

陈旧性不稳定型骨质疏松脊柱骨折PVP治疗疗效观察

目的 探讨经皮椎体成形术(PVP)治疗陈旧性不稳定型骨质疏松脊柱骨折的临床疗效.方法 根据影像学将20例骨质疏松陈旧性单椎体骨折分为稳定型、不稳定型两组,每组10例,均应用PVP治疗.观察两组患者术前30 min及术后6h、3d、30 d弯腰活动时数字模拟评分(VAS),比较术前、术后伤椎节段站立位与平卧位X线片椎体前缘高度水平.结果 术前30min弯腰时两组患者的VAS评分比较差异有统计学意义(P＜0.05).与术前30 min比较,两组患者术后各观测点VAS评分明显降低,差异有统计学意义(P＜0.05).术后6h、3d、30 d弯腰时两组VAS评分比较,差异无统计学意义(P＞0.05).稳定型组术前、术后椎体前缘高度比较差异无统计学意义(P＞0.05);不稳定型组术后站立位、平卧位椎体前缘高度较术前明显改变,差异有统计学意义(P＜0.05).结论 不稳定型骨质疏松脊柱骨折术前疼痛较稳定型明显,但PVP治疗后二者效果类似;不稳定型骨质疏松脊柱骨折PVP术后高度可得到一定的恢复.     

扶肺固肾饮对慢性阻塞性肺疾病稳定期患者BODE指数的影响

【目的】观察扶肺固肾饮对慢性阻塞性肺疾病(COPD)稳定期重度、极重度,且中医证型为肺肾两虚夹痰瘀证患者BODE指数(B为体质量指数,O为气流阻塞程度,D为呼吸困难,E为运动耐力)的影响。【方法】将80例患者随机分为治疗组和对照组各40例。对照组给予吸入沙美特罗替卡松粉吸入剂(舒利迭)治疗,治疗组在对照组基础上加用扶肺固肾饮口服治疗。2组疗程均为3个月。比较2组患者治疗前后体质量指数(BMI)、气流阻塞程度[第1秒用力呼气容积占预计值百分比(FEV1%)]、呼吸困难指数(MMRC)、运动耐力[6 min步行距离(6MWT)]指标的变化情况。【结果】(1)组内比较:治疗组重度、极重度患者FEV1%、MMRC、6MWT治疗后积分及BODE指数治疗后总分均较治疗前改善(P0.05),BMI无明显改善(P0.05);对照组重度、极重度患者MMRC、6MWT治疗后积分及BODE指数治疗后总分均较治疗前改善(P0.05),FEV1%、BMI无明显改善(P0.05)。(2)组间比较:除BMI外,治疗组FEV1%、MMRC、6MWT治疗后积分及BODE指数治疗后总分均较对照组治疗后明显改善(P0.05)。【结论】扶肺固肾饮联合舒利迭吸入能显著降低COPD稳定期患者的BODE指数积分,改善COPD稳定期患者的临床症状、肺功能和运动耐力,提高患者生活质量。     

吸入噻托溴铵联合信必可治疗稳定期中重度COPD的有效性与安全性

目的探讨吸入噻托溴铵联合信必可治疗稳定期中重度慢性阻塞性肺疾病(COPD)的有效性与安全性。方法将2015年1月~2017年1月在我院接受治疗的60例稳定期中重度COPD患者作为研究对象,并给予随机分组,对照组30例给予单纯信必可吸入治疗;干预组30例,在对照组基础上加用噻托溴铵治疗,对两组患者治疗前后的肺功能相关指标、临床症状评分、临床治疗效果以及不良反应发生情况进行综合评价。结果干预组患者治疗后的FEV1、FVC、FEV1/FVC等肺功能指标显著优于对照组,差异有统计学意义(P0.05);干预组治疗1个月、2个月后的临床症状评分与对照组比较有明显差异(P0.05);且干预组治疗后有28例患者显示有效,占93.3%,显著高于对照组的70.0%,差异有统计学意义(P0.05);干预组患者治疗后不良反应发生率仅为6.7%,显著低于对照组的23.3%,差异有统计学有意义(P0.05)。结论采用吸入噻托溴铵联合信必可治疗稳定期中重度COPD,能够促进患者临床症状缓解,改善肺功能,疗效优于单纯信必可治疗,值得推广应用。     

The development of mechanically formed stable nanobubbles intended for sonoporation-mediated gene transfection

In this study, stable nano-sized bubbles (nanobubbles [NBs]) were produced using the mechanical agitation method in the presence of perfluorocarbon gases. NBs made with perfluoropropane had a smaller size (around 400?nm) compared to that of those made with perfluorobutane or nitrogen gas. The lipid concentration in NBs affected both their initial size and post-formulation stability. NBs formed with a final lipid concentration of 0.5?mg/ml tended to be more stable, having a uniform size distribution for 24?h at room temperature and 50?h at 4?°C. In vitro gene expression revealed that NBs/pDNA in combination with ultrasound (US) irradiation had significantly higher transfection efficacy in colon C26 cells. Moreover, for in vivo gene transfection in mice left limb muscles, there was notable local transfection activity by NBs/pDNA when combined with US irradiation. In addition, the aged NBs kept at room temperature or 4?°C were still functional at enhancing gene transfection in mice. We succeeded in preparing stable NBs for efficient in vivo gene transfection, using the mechanical agitation method.     

ETN及弹性髓内钉在胫腓骨中下段骨折中的应用

目的 总结解剖型髓内钉(ETN)及弹性髓内钉在胫腓骨中下段骨折的临床疗效及优势.方法 本科自2013年9月至2016年6月采用ETN及弹性髓内钉治疗胫腓骨中下段骨折31例,其中男20例,女11例,年龄21 ～ 68岁,平均43岁.结果 全部病例均获随访,随访时间8～24个月,平均16个月,所有病例均获骨性愈合,无畸形愈合发生,愈合时间12～28周,平均15周.按Johner-Wruhs评分标准:优24例,良5例,可2例,优良率93.5％.结论 ETN及弹性髓内钉治疗胫腓骨中下段骨折具有固定稳定性强、创伤损伤小、骨折愈合率高、畸形愈合率低、有利于早期进行功能康复等优点,是一种理想的内固定选择.     

Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations

PurposeTo retrospectively investigate the safety and benefit of gefitinib plus transarterial infusion (TAI) therapy as a first-line treatment compared to gefitinib alone for patients with large (>7 cm) nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.Materials and MethodsBetween January 2010 and December 2013, 92 consecutive treatment-naïve patients with large NSCLC with EGFR mutations, who were treated using gefitinib plus TAI (G+T, n = 42) or gefitinib alone (G, n = 50) were reviewed. The primary endpoints were the objective response rate (ORR) and tumor reduction rate. The secondary endpoints were progression-free survival (PFS) and overall survival (OS), and safety was also assessed.ResultsThe baseline characteristics of the 2 groups were balanced, and no patients experienced treatment-related death. Toxicity outcomes did not differ between the G+T and G groups. The tumor reduction rate in the G+T group was significantly higher than that in the G group (42.9 vs 31.9%, P = .028). The ORR was 83% in the G+T group and 72% in the G group (P = .197). The median PFS was significantly longer in the G+T group than in the G group (14.0 vs 10.0 months, P = .023). The median OS was 30.0 months in the G+T group and 27.0 months in the G group (P = .235).ConclusionsThis study suggests that compared with gefitinib alone, combination therapy with gefitinib plus TAI was well tolerated and potentially improved the tumor reduction rate and PFS in patients with large NSCLC with EGFR mutations.     

长期吸入糖皮质激素联合最大负荷吸气肌训练对稳定期慢性阻塞性肺疾病症状缓解及运动耐力的影响

目的 探讨长期吸入糖皮质激素联合最大负荷吸气肌训练对稳定期慢性阻塞性肺疾病(COPD)症状缓解及运动耐力的影响。方法 选取2019年7月—2022年2月江南大学附属医院收治的124例稳定期COPD患者,按随机数字表法将其分为研究组与对照组,每组62例。对照组接受长期吸入糖皮质激素治疗,研究组在对照组基础上另给予最大负荷吸气肌训练。两组均治疗6个月。比较两组肺功能、呼吸困难程度、免疫功能、运动耐力及生活质量。结果 研究组治疗前后第1秒用力呼气容积(FEV₁)、用力肺活量(FVC)、FEV₁/FVC的差值高于对照组(P<0.05)。研究组治疗前后MRC呼吸困难量表评分的差值高于对照组(P<0.05)。研究组治疗前后CD3⁺、CD4⁺、CD4⁺/CD8⁺的差值高于对照组(P<0.05)。研究组治疗前后6 min步行距离的差值高于对照组(P<0.05)。研究组治疗前后COPD自我评估测试问卷评分的差值高于对照组(P<0.05)。结论 ...     

Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope

Summary The systemic elimination of nicardipine has been studied by an initial oral administration of nicardipine followed 1.25 h later by intravenous injection of the deuterium-labelled molecule (D₃ nicardipine).To check that intravenous kinetics was not modified by the oral administration, an i.v. injection of unlabelled nicardipine (D₀ nicardipine) was also given. The study was carried out in six healthy male volunteers, aged between 24 and 27 years, according to a Latin square cross-over design.Similar values were found for each kinetic parameter after i.v. administration regardless of whether it was administered alone by that route or with an oral dose. The plasma level-time curves of nicardipine were described by a three open compartment model. The total plasma clearance was about 800 ml/min, the volume of distribution was of the order of 1 l/kg and the half-life of -elimination ranged from 4 to 5 h. The elimination rate constant was independent of the route of administration.